Affiliation:
1. Department of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo Japan
2. Department of Chemotherapy The University of Tokyo Hospital Tokyo Japan
3. Department of Endoscopy and Endoscopic Surgery The University of Tokyo Hospital Tokyo Japan
4. Department of Pathology The University of Tokyo Hospital Tokyo Japan
Abstract
AbstractAimComprehensive genomic profiling (CGP) test for solid tumors is now increasingly utilized in clinical practice, especially in pancreatobiliary cancer, and specimens obtained by endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) are often submitted for tissue‐based CGP test. In this study, we evaluated the feasibility of EUS‐TA using a 22‐gauge Franseen needle for the CGP test.MethodsConsecutive patients with solid tumors who underwent EUS‐TA using a 22‐gauge Franseen needle, and whose tissue samples were pre‐checked for suitability for CGP test, were included in this single‐center, retrospective analysis. The success rates of appropriate sample collection for CGP evaluated by pathologists (1st quality control) and CGP test (2nd quality control) were evaluated. In addition, The EUS‐TA slides were evaluated for the tissue area and tumor area content, using the image software.ResultsA total of 50 cases, with 78% of pancreatic cancer, were included in the analysis. A median of 3 passes of EUS‐TA were performed with an adverse event rate of 4%. The success rates for 1st and 2nd quality control for CGP tests were 86% and 76%, respectively. The image analyses suggested EUS‐TA specimen did not always fulfill CGP test criteria, with 18% of tissue area ≥16 mm2 and 38% of tumor area content ≥20%, even in cases with successful CGP tests. The suction method yielded a significantly larger amount of DNA but without a significant difference in the multivariate analysis.ConclusionsThe present study demonstrated the feasibility of EUS‐TA using a 22‐gauge Franseen needle for CGP test.